{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:22:24Z","timestamp":1792466544588,"version":"4.5.0"},"reference-count":250,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Signals that influence the differentiation and function of cells of the osteoblast lineage play a role in the mechanism of action of anabolic agents in the skeleton. Wnts induce the differentiation of mesenchymal stem cells toward osteoblasts, and insulin-like growth factor I (IGF-I) enhances the function of mature osteoblasts. The activity of Wnt and IGF-I is controlled by proteins that bind to the growth factor or to its receptors. Sclerostin is a Wnt antagonist that binds to Wnt co-receptors and prevents Wnt signal activation. Teriparatide, a 1\u201334 amino terminal fragment of parathyroid hormone (PTH), and abaloparatide, a modified 1\u201334 amino terminal fragment of PTH-related peptide (PTHrp), induce IGF-I, increase bone mineral density (BMD), reduce the incidence of vertebral and non-vertebral fractures and are approved for the treatment of postmenopausal osteoporosis. Romosozumab, a humanized anti-sclerostin antibody, increases bone formation, decreases bone resorption, increases BMD and reduces the incidence of vertebral fractures. An increased incidence of cardiovascular events has been associated with romosozumab, which is yet to be approved for the treatment of osteoporosis. In conclusion, cell and molecular studies have formed the foundation for the development of new anabolic therapies for osteoporosis with proven efficacy on the incidence of new fractures.<\/jats:p>","DOI":"10.1530\/eje-17-0920","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T01:40:27Z","timestamp":1510105227000},"page":"R33-R44","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":80,"title":["MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis"],"prefix":"10.1093","volume":"178","author":[{"given":"Ernesto","family":"Canalis","sequence":"first","affiliation":[{"name":"Departments of Orthopaedic Surgery and Medicine, UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"ref431","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women.","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/en.2006-1352","article-title":"The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes","volume":"148","year":"2007","journal-title":"Endocrinology"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/endo.141.7.7585","article-title":"Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation","volume":"141","year":"2000","journal-title":"Endocrinology"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1210\/endo.142.10.8436","article-title":"Evidence that anabolic effects of PTH on bone require IGF-I in growing mice","volume":"142","year":"2001","journal-title":"Endocrinology"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.2001.16.9.1583","article-title":"The bone remodeling compartment: a circulatory function for bone lining cells","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","article-title":"Update on Wnt signaling in bone cell biology and bone disease","volume":"492","year":"2012","journal-title":"Gene"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/301721","article-title":"Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21","volume":"62","year":"1998","journal-title":"American Journal of Human Genetics"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","article-title":"Essential role of beta-catenin in postnatal bone acquisition","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","article-title":"Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis","volume":"8","year":"2005","journal-title":"Developmental Cell"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","year":"2004","journal-title":"Toxicologic Pathology"},{"key":"ref121","first-page":"51","article-title":"Bone morphogenetic proteins and their antagonists","volume":"7","year":"2006","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","article-title":"Abaloparatide: first global approval.","volume":"77","year":"2017","journal-title":"Drugs"},{"key":"ref1991","first-page":"3864","article-title":"Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa","volume":"81","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","year":"2017","journal-title":"Bone"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/382638a0","article-title":"Functional interaction of beta-catenin with the transcription factor LEF-1","volume":"382","year":"1996","journal-title":"Nature"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","year":"2001","journal-title":"Human Molecular Genetics"},{"key":"ref1131","article-title":"Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","year":"2008","journal-title":"Endocrine Reviews"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","year":"2013","journal-title":"Nature Reviews Endocrinology"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","year":"2001","journal-title":"American Journal of Human Genetics"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","year":"2003","journal-title":"Journal of Cell Science"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)81925-X","article-title":"Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF","volume":"88","year":"1997","journal-title":"Cell"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.2001.16.9.1583","article-title":"The bone remodeling compartment: a circulatory function for bone lining cells","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2006.12.014","article-title":"Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling","volume":"391","year":"2007","journal-title":"Gene"},{"key":"ref2381","article-title":"Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref51","first-page":"529","article-title":"Skeletal growth factors","year":"2007","journal-title":"Osteoporosis"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.","volume":"107","year":"2001","journal-title":"Cell"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1073\/pnas.0408742102","article-title":"Regulation of osteoblastogenesis and bone mass by Wnt10b.","volume":"102","year":"2005","journal-title":"PNAS"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI37175","article-title":"Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice","volume":"119","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/jbmr.5650101203","article-title":"Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women","volume":"10","year":"1995","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.","volume":"107","year":"2001","journal-title":"Cell"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1210\/endo.131.3.1505451","article-title":"Insulin-like growth factor-I supports formation and activation of osteoclasts","volume":"131","year":"1992","journal-title":"Endocrinology"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1210\/jcem.87.6.8574","article-title":"Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa","volume":"87","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI37175","article-title":"Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice","volume":"119","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/EJE-12-1074","article-title":"Serum sclerostin levels in men with idiopathic osteoporosis","volume":"168","year":"2013","journal-title":"European Journal of Endocrinology: Oslo"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","article-title":"Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMe1711298","article-title":"Romosozumab \u2013 promising or practice changing?","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1371","first-page":"51","article-title":"Bone morphogenetic proteins and their antagonists","volume":"7","year":"2006","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1210\/er.2002-0023","article-title":"Bone morphogenetic proteins, their antagonists, and the skeleton","volume":"24","year":"2003","journal-title":"Endocrine Reviews"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","year":"2005","journal-title":"Developmental Cell"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384 in a 2-year study in Fischer 344 rats","volume":"34","year":"2006","journal-title":"Toxicologic Pathology"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","article-title":"Update on Wnt signaling in bone cell biology and bone disease","volume":"492","year":"2012","journal-title":"Gene"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1210\/endo.142.10.8436","article-title":"Evidence that anabolic effects of PTH on bone require IGF-I in growing mice","volume":"142","year":"2001","journal-title":"Endocrinology"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.1102836","article-title":"TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis","volume":"188","year":"2012","journal-title":"Journal of Immunology"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"ref1761","doi-asserted-by":"publisher","first-page":"201031","DOI":"10.1002\/humu.21274","article-title":"missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function https org","journal-title":"Human Mutation"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","year":"2003","journal-title":"EMBO Journal"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.1207188109","article-title":"Targeted deletion of Sost distal enhancer increases bone formation and bone mass","volume":"109","year":"2012","journal-title":"PNAS"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","article-title":"Linking colorectal cancer to Wnt signaling","volume":"103","year":"2000","journal-title":"Cell"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","year":"2002","journal-title":"Cell"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","year":"2002","journal-title":"American Journal of Human Genetics"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/jbmr.5650101203","article-title":"Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women","volume":"10","year":"1995","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1359\/jbmr.081235","article-title":"Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell .. and more","volume":"34","year":"2013","journal-title":"Endocrine Reviews"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","year":"2006","journal-title":"Cell"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","article-title":"Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis","volume":"30","year":"2010","journal-title":"Molecular and Cellular Biology"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","year":"2002","journal-title":"Journal of Medical Genetics"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.060610","article-title":"Role of IGF-I signaling in regulating osteoclastogenesis","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","year":"2003","journal-title":"American Journal of Human Genetics"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","year":"2007","journal-title":"Bone"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.","volume":"17","year":"2006","journal-title":"Osteoporosis International"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.1074\/jbc.M609509200","article-title":"LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-006-9005-1","article-title":"Anorexia nervosa and osteoporosis","volume":"7","year":"2006","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2006.12.014","article-title":"Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling","volume":"391","year":"2007","journal-title":"Gene"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11154-005-5226-y","article-title":"Current guidelines for adult GH replacement","volume":"6","year":"2005","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","year":"2003","journal-title":"Journal of Cell Science"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","year":"2005","journal-title":"Developmental Cell"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/EJE-12-1074","article-title":"Serum sclerostin levels in men with idiopathic osteoporosis","volume":"168","year":"2013","journal-title":"European Journal of Endocrinology: Oslo"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bone.2012.10.009","article-title":"Novel SOST gene mutation in a sclerosteosis patient and her parents","volume":"52","year":"2013","journal-title":"Bone"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","article-title":"Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"ref1301","first-page":"529","article-title":"Skeletal growth factors","year":"2007","journal-title":"Osteoporosis"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.1102836","article-title":"TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis","volume":"188","year":"2012","journal-title":"Journal of Immunology"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/endo.141.7.7585","article-title":"Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation","volume":"141","year":"2000","journal-title":"Endocrinology"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/301721","article-title":"Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21","volume":"62","year":"1998","journal-title":"American Journal of Human Genetics"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","article-title":"Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1359\/jbmr.090226","article-title":"Serum IGF-1 determines skeletal strength by regulating sub-periosteal expansion and trait interactions","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","year":"2007","journal-title":"Bone"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell .. and more","volume":"34","year":"2013","journal-title":"Endocrine Reviews"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","year":"2013","journal-title":"Bone"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11154-005-5226-y","article-title":"Current guidelines for adult GH replacement","volume":"6","year":"2005","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.abb.2008.03.006","article-title":"Wnt signaling: a win for bone","volume":"473","year":"2008","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.1207188109","article-title":"Targeted deletion of Sost distal enhancer increases bone formation and bone mass","volume":"109","year":"2012","journal-title":"PNAS"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0092-8674(02)00685-2","article-title":"Control of beta-catenin phosphorylation\/degradation by a dual-kinase mechanism","volume":"108","year":"2002","journal-title":"Cell"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","year":"2005","journal-title":"Genome Research"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jbmr.1773","article-title":"Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels","volume":"28","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/JBMR.050210","article-title":"TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro","volume":"20","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","year":"2004","journal-title":"Journal of Experimental Medicine"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","year":"2016","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","year":"2013","journal-title":"Bone"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","article-title":"Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation","volume":"35","year":"2004","journal-title":"Bone"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI9017","article-title":"Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover","volume":"105","year":"2000","journal-title":"Journal of Clinical Investigation"},{"key":"ref741","first-page":"3864","article-title":"Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa","volume":"81","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMe1711298","article-title":"Romosozumab \u2013 promising or practice changing?","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","year":"2011","journal-title":"Molecular and Cellular Biology"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"31720","DOI":"10.1074\/jbc.M602308200","article-title":"Wnt\/beta-catenin signaling is a normal physiological response to mechanical loading in bone","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","year":"2001","journal-title":"Human Molecular Genetics"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0092-8674(02)00685-2","article-title":"Control of beta-catenin phosphorylation\/degradation by a dual-kinase mechanism","volume":"108","year":"2002","journal-title":"Cell"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","year":"1989","journal-title":"Journal of Clinical Investigation"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.","volume":"17","year":"2006","journal-title":"Osteoporosis International"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","year":"2012","journal-title":"Bone"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","year":"2017","journal-title":"Mayo Clinic Proceedings"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","year":"2001","journal-title":"American Journal of Human Genetics"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jbmr.1773","article-title":"Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels","volume":"28","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1359\/jbmr.090226","article-title":"Serum IGF-1 determines skeletal strength by regulating sub-periosteal expansion and trait interactions","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI9017","article-title":"Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover","volume":"105","year":"2000","journal-title":"Journal of Clinical Investigation"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/382638a0","article-title":"Functional interaction of beta-catenin with the transcription factor LEF-1","volume":"382","year":"1996","journal-title":"Nature"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","year":"2004","journal-title":"Toxicologic Pathology"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","year":"2002","journal-title":"American Journal of Human Genetics"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin.","volume":"283","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","year":"2017","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.abb.2008.03.006","article-title":"Wnt signaling: a win for bone","volume":"473","year":"2008","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"38239","DOI":"10.1074\/jbc.M206402200","article-title":"Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women.","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","article-title":"Abaloparatide: first global approval.","volume":"77","year":"2017","journal-title":"Drugs"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","year":"2017","journal-title":"Mayo Clinic Proceedings"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1210\/jc.2009-2677","article-title":"Update in new anabolic therapies for osteoporosis","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/17446651.1.1.47","article-title":"Skeletal actions of insulin-like growth factors","volume":"1","year":"2006","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","article-title":"Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis","volume":"30","year":"2010","journal-title":"Molecular and Cellular Biology"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","article-title":"Linking colorectal cancer to Wnt signaling","volume":"103","year":"2000","journal-title":"Cell"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/endo-126-4-1806","article-title":"Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis","volume":"126","year":"1990","journal-title":"Endocrinology"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","article-title":"Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis","volume":"8","year":"2005","journal-title":"Developmental Cell"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin.","volume":"283","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1210\/jc.2009-2677","article-title":"Update in new anabolic therapies for osteoporosis","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","article-title":"Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation","volume":"35","year":"2004","journal-title":"Bone"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1185\/030079906X100159","article-title":"Initial experience with teriparatide in the United States","volume":"22","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"31720","DOI":"10.1074\/jbc.M602308200","article-title":"Wnt\/beta-catenin signaling is a normal physiological response to mechanical loading in bone","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","year":"2006","journal-title":"Journal of Clinical Investigation"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/17446651.1.1.47","article-title":"Skeletal actions of insulin-like growth factors","volume":"1","year":"2006","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","year":"2003","journal-title":"American Journal of Human Genetics"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/PL00000744","article-title":"Structure and function of the type 1 insulin-like growth factor receptor","volume":"57","year":"2000","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","year":"2013","journal-title":"Nature Reviews Endocrinology"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","year":"2005","journal-title":"Genome Research"},{"key":"ref731","first-page":"4257","article-title":"Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study","volume":"83","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","year":"2002","journal-title":"Journal of Medical Genetics"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.1074\/jbc.M609509200","article-title":"LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST","volume":"281","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","year":"2006","journal-title":"Journal of Clinical Investigation"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/PL00000744","article-title":"Structure and function of the type 1 insulin-like growth factor receptor","volume":"57","year":"2000","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMe058080","article-title":"The fate of circulating osteoblasts","volume":"352","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","year":"2004","journal-title":"Journal of Experimental Medicine"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bone.2012.10.009","article-title":"Novel SOST gene mutation in a sclerosteosis patient and her parents","volume":"52","year":"2013","journal-title":"Bone"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384 in a 2-year study in Fischer 344 rats","volume":"34","year":"2006","journal-title":"Toxicologic Pathology"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1210\/jcem.87.6.8574","article-title":"Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa","volume":"87","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","year":"1992","journal-title":"Osteoporosis International"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","year":"1989","journal-title":"Journal of Clinical Investigation"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","year":"2016","journal-title":"Endocrinology"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","year":"2017","journal-title":"Bone"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-006-9005-1","article-title":"Anorexia nervosa and osteoporosis","volume":"7","year":"2006","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","year":"2016","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref511","doi-asserted-by":"publisher","first-page":"201031","DOI":"10.1002\/humu.21274","article-title":"missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function https org","journal-title":"Human Mutation"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1210\/er.2002-0023","article-title":"Bone morphogenetic proteins, their antagonists, and the skeleton","volume":"24","year":"2003","journal-title":"Endocrine Reviews"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","article-title":"Essential role of beta-catenin in postnatal bone acquisition","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","year":"2017","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","article-title":"Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/endo-126-4-1806","article-title":"Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis","volume":"126","year":"1990","journal-title":"Endocrinology"},{"key":"ref1981","first-page":"4257","article-title":"Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study","volume":"83","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.060610","article-title":"Role of IGF-I signaling in regulating osteoclastogenesis","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2017.06.027","article-title":"Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes","volume":"103","year":"2017","journal-title":"Bone"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)81925-X","article-title":"Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF","volume":"88","year":"1997","journal-title":"Cell"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","year":"2008","journal-title":"Endocrine Reviews"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis","volume":"27","year":"2000","journal-title":"Bone"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2017.06.027","article-title":"Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes","volume":"103","year":"2017","journal-title":"Bone"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"38239","DOI":"10.1074\/jbc.M206402200","article-title":"Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","year":"2006","journal-title":"Cell"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","year":"1992","journal-title":"Osteoporosis International"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/JBMR.050210","article-title":"TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro","volume":"20","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1210\/endo.131.3.1505451","article-title":"Insulin-like growth factor-I supports formation and activation of osteoclasts","volume":"131","year":"1992","journal-title":"Endocrinology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","year":"2011","journal-title":"Molecular and Cellular Biology"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMe058080","article-title":"The fate of circulating osteoblasts","volume":"352","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/en.2006-1352","article-title":"The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes","volume":"148","year":"2007","journal-title":"Endocrinology"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1359\/jbmr.081235","article-title":"Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","year":"2016","journal-title":"Endocrinology"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1185\/030079906X100159","article-title":"Initial experience with teriparatide in the United States","volume":"22","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","year":"2002","journal-title":"Cell"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","year":"2012","journal-title":"Bone"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/en.2003-0350","article-title":"Parallel phosphatidylinositol-3 kinase and p42\/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells","volume":"144","year":"2003","journal-title":"Endocrinology"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1073\/pnas.0408742102","article-title":"Regulation of osteoblastogenesis and bone mass by Wnt10b.","volume":"102","year":"2005","journal-title":"PNAS"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","year":"2003","journal-title":"EMBO Journal"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/en.2003-0350","article-title":"Parallel phosphatidylinositol-3 kinase and p42\/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells","volume":"144","year":"2003","journal-title":"Endocrinology"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis","volume":"27","year":"2000","journal-title":"Bone"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/178\/2\/EJE-17-0920.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-0920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:51:30Z","timestamp":1719575490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/178\/2\/R33\/6655220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":250,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-0920","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}